Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

This study has been terminated.
(Terminated by sponsor due to lack of funding)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT00524459
First received: August 31, 2007
Last updated: January 31, 2013
Last verified: January 2013
  Purpose

RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them before surgery may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects of giving liposomal doxorubicin together with docetaxel before surgery and to see how well it works in treating women with locally advanced breast cancer that can be removed by surgery.


Condition Intervention Phase
Breast Cancer
Drug: docetaxel
Drug: pegylated liposomal doxorubicin hydrochloride
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Primary Purpose: Treatment
Official Title: Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Docetaxel in Locally Advanced Operable Breast Cancer

Resource links provided by NLM:


Further study details as provided by Roswell Park Cancer Institute:

Primary Outcome Measures:
  • Pathological complete response [ Designated as safety issue: No ]
  • Clinical complete response [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall clinical local regional response [ Designated as safety issue: No ]
  • Number of women who would have required a mastectomy upfront but who underwent breast conservation therapy instead after neoadjuvant chemotherapy [ Designated as safety issue: No ]
  • Safety, in terms of neutropenia and cardiac toxicity [ Designated as safety issue: Yes ]

Enrollment: 6
Study Start Date: May 2007
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

Primary

  • To evaluate the rate of pathological complete response and clinical complete response in women with locally advanced breast cancer treated with pegylated doxorubicin hydrochloride liposome and docetaxel.

Secondary

  • To assess the overall clinical local regional response in patients treated with this preoperative chemotherapy regimen.
  • To evaluate the number of patients who would have required a mastectomy upfront but who underwent breast conservation therapy instead after neoadjuvant chemotherapy.
  • To assess the safety, particularly with regard to neutropenia and cardiac toxicity, of pegylated doxorubicin hydrochloride liposome and docetaxel.

OUTLINE: This is a multicenter study.

Patients receive pegylated doxorubicin hydrochloride liposome IV over 90 minutes and docetaxel IV over 90 minutes on day 1. Patients receive pegylated filgrastim subcutaneously on days 2 or 3 post-chemotherapy in courses 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Within 8 weeks after completion of chemotherapy, patients undergo a lumpectomy or mastectomy to remove the tumor. Some patients may receive additional therapy after surgery, including hormonal therapy, chemotherapy, or radiotherapy.

After completion of study therapy, patients are followed periodically for up to 5 years.

  Eligibility

Ages Eligible for Study:   up to 64 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed breast cancer using core biopsies

    • Locally advanced disease
    • Resectable disease
    • Fine needle aspiration cytology allowed and must demonstrate invasive adenocarcinoma
  • No more than 8 weeks since initial cytologic or histologic diagnosis of breast cancer
  • Tumor must meet the following criteria:

    • Palpable on clinical examination and confined to either the breast or to the breast and ipsilateral axilla
    • Measured clinically as greater than 2 cm in size (T2)
  • Patients with skeletal pain are eligible if bone scan and/or roentgenological examination fail to disclose metastatic disease

    • Suspicious findings must be confirmed as benign by x-ray, MRI scan, or biopsy
  • Hormonal status not specified

PATIENT CHARACTERISTICS:

Inclusion criteria:

  • Female
  • Menopausal status not specified
  • ECOG performance status 0-2
  • Life expectancy ≥ 10 years
  • Platelet count ≥ 100,000/mm³
  • ANC ≥ 1,500/mm³
  • Hemoglobin ≥ 9.0 g/dL
  • Bilirubin normal
  • AST or ALT normal
  • Alkaline phosphatase normal
  • Serum creatinine normal
  • Negative pregnancy test
  • Fertile patients must use effective contraception (e.g., abstinence, intrauterine device, barrier device with spermicide, or surgical sterilization) during and for 3 months after completion of study therapy
  • Normal cardiac function by LVEF or MUGA scan
  • Patients with prior non-breast malignancies are eligible if they have been disease-free for ≥ 10 years

    • The following are allowed even if diagnosed within the past 10 years:

      • Squamous or basal cell carcinoma of the skin that has been effectively treated
      • Carcinoma in situ of the cervix that has been treated by operation only
      • Lobular carcinoma in situ of the ipsilateral or contralateral breast treated by segmental resection only

Exclusion criteria:

  • Pregnant or lactating women
  • Male patients
  • Hyperbilirubinemia
  • Female patients with 1 or more of the following conditions:

    • Ulceration, erythema, infiltration of the skin (complete fixation), or peau d'orange (edema) of any magnitude

      • Tethering or dimpling of the skin or nipple inversion should not be interpreted as skin infiltration
    • Ipsilateral lymph nodes that are clinically fixed to one another or to other structures (N2 disease)
    • Bilateral malignancy or a mass in the opposite breast suspicious for malignancy, unless there is biopsy proof that the mass is not malignant
    • Suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless there is biopsy evidence that these are not involved with the tumor
  • Nonmalignant systemic disease (e.g., cardiovascular, renal, or hepatic) that would preclude study therapy
  • Active cardiac disease that would preclude the use of doxorubicin hydrochloride, including any of the following:

    • Documented myocardial infarction
    • Angina pectoris that requires the use of antianginal medication
    • History of documented New York Heart Association class II-IV heart failure
    • Valvular disease with documented cardiac function compromise
    • Poorly controlled hypertension (i.e., diastolic BP > 100 mm Hg)

      • Patients with well-controlled hypertension and on medication are eligible for study
  • Psychiatric or addictive disorders that would preclude obtaining informed consent

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

  • Concurrent noncancer therapies allowed if used for conditions other than breast cancer
  • Adjuvant therapy after surgery allowed

Exclusion criteria:

  • Prior radiotherapy, chemotherapy, immunotherapy, and/or hormonal therapy for breast cancer
  • Prior anthracycline therapy for any condition
  • Concurrent hormonal therapy including tamoxifen, aromatase inhibitors, or raloxifene
  • Concurrent sex hormonal therapy including birth-control pills or ovarian hormonal replacement therapy
  • Concurrent other cancer therapy
  • Concurrent herbal or alternative therapies for breast cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00524459

Locations
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263-0001
Sponsors and Collaborators
Roswell Park Cancer Institute
Investigators
Principal Investigator: Tracey O'Connor, MD Roswell Park Cancer Institute
  More Information

No publications provided

Responsible Party: Roswell Park Cancer Institute
ClinicalTrials.gov Identifier: NCT00524459     History of Changes
Other Study ID Numbers: I 75506, RPCI-I-75506
Study First Received: August 31, 2007
Last Updated: January 31, 2013
Health Authority: United States: Federal Government

Keywords provided by Roswell Park Cancer Institute:
stage IIIA breast cancer
stage IIIB breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Doxorubicin
Docetaxel
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 23, 2014